Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients

详细信息    查看全文

• 作者：Wende Hao ; Xuhui Zhang ; Bingshui Xiu ; Xiqin Yang ; Shuofeng Hu…
• 刊名：Tumor Biology
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：37
• 期：7
• 页码：8909-8916
• 全文大小：1,307 KB
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380
• 卷排序：37

文摘

Breast cancer is the most common cancer in women worldwide, identification of new biomarkers for early diagnosis and detection will improve the clinical outcome of breast cancer patients. In the present study, we determined serum levels of vitronectin (VN) in 93 breast cancer patients, 30 benign breast lesions, 9 precancerous lesions, and 30 healthy individuals by enzyme-linked immunosorbent assays. Serum VN level was significantly higher in patients with stage 0–I primary breast cancer than in healthy individuals, patients with benign breast lesion or precancerous lesions, as well as those with breast cancer of higher stages. Serum VN level was significantly and negatively correlated with tumor size, lymph node status, and clinical stage (p < 0.05 in all cases). In addition, VN displayed higher area under curve (AUC) value (0.73, 95 % confidence interval (CI) [0.62–0.84]) than carcinoembryonic antigen (CEA) (0.64, 95 % CI [0.52–0.77]) and cancer antigen 15-3 (CA 15-3) (0.69, 95 % CI [0.58–0.81]) when used to distinguish stage 0–I cancer and normal control. Importantly, the combined use of three biomarkers yielded an improvement in receiver operating characteristic curve with an AUC of 0.83, 95 % CI [0.74–0.92]. Taken together, our current study showed for the first time that serum VN is a promising biomarker for early diagnosis of breast cancer when combined with CEA and CA15-3.KeywordsBreast cancerEarly stageSerumDiagnosis